Phase 3 Readout
SLGL: Phase 3 Topline: A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Pa
October 1, 2026 · patidegib. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- Sol-Gel Technologies Ltd. (SLGL)
- Drug
- patidegib
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Pa
- Drug
- patidegib
- Indication
- Gorlin Syndrome